McKesson Corporation opened fiscal 2027 with an earnings beat, double-digit adjusted operating profit growth and higher full-year earnings guidance. First-quarter adjusted earnings rose 20% to $9.93 per share, topping the Zacks Consensus Estimate of $9.44 by 5.2%, while revenues increased 8% to $105.38 billion. Adjusted operating profit advanced 16% to $1.65 billion, driven by growth in North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions. Oncology & Multispecialty revenues climbed 33% to $14.22 billion and adjusted operating profit increased 41% to $405 million, with the U.S. Oncology Network reaching approximately 3,400 providers treating more than 2 million patients annually. GLP-1 distribution revenue reached $15 billion in the quarter, up 24% year over year and 13% sequentially. McKesson raised fiscal 2027 adjusted earnings guidance to $44.20-$45.00 per share from $43.80-$44.60, implying 13%-15% growth, and maintained free cash flow guidance of $4.5-$4.9 billion with about $5 billion of share repurchases expected for the year.
McKesson CorporationMcKesson beat Q1 estimates, raised FY27 guidance, and reported strong growth in oncology and GLP-1 distribution.
Cardinal Health Inc
Cencora Inc.